(S)-2-((S)-3-Benzyloxycarbonyl-2-{3-[3-(4-cyano-phenoxy)-propyl]-ureido}-propionylamino)-3-methyl-butyric acid benzyl ester | 147867-06-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-((S)-3-Benzyloxycarbonyl-2-{3-[3-(4-cyano-phenoxy)-propyl]-ureido}-propionylamino)-3-methyl-butyric acid benzyl ester
• CAS: 147867-06-9
• 化学式: C₃₄H₃₈N₄O₇
• 分子量: 614.698
• InChiKey: LVSFBVAXGRQHES-SMCANUKXSA-N

物化性质

• 沸点：
  846.7±65.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.01
• 重原子数：
  45.0
• 可旋转键数：
  16.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  155.85
• 氢给体数：
  3.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (S)-2-((S)-3-Benzyloxycarbonyl-2-{3-[3-(4-cyano-phenoxy)-propyl]-ureido}-propionylamino)-3-methyl-butyric acid benzyl ester 在 硫化氢 、 ammonium acetate 、 三乙胺 作用下， 以 吡啶 、 甲醇 、 丙酮 为溶剂， 反应 21.0h， 生成 (S)-2-((S)-3-Benzyloxycarbonyl-2-{3-[3-(4-carbamimidoyl-phenoxy)-propyl]-ureido}-propionylamino)-3-methyl-butyric acid benzyl ester; hydriodide
  参考文献：
  名称：

  Design, synthesis, and evaluation of orally active fibrinogen inhibitors

  摘要：

  Low molecular weight and orally active fibrinogen inhibitors are described. The compounds studied in this work were rationally designed based on a metabolic study of a peptidic fibrinogen inhibitor, 4-(4-amidinophenoxy)butanoylaspartylvaline (1, FK633), which led to the synthesis of a potent and orally active antiplatelet agent, 4-(4-amidinophenoxy)butanoylaspartylvalylthiomorpholine 1,1-dioxide (3 f, FR158999). (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00055-3
• 作为产物：
  描述：

  4-(4-cyanophenoxy)butanoic acid 、 L-(α-O-benzylaspartyl)-L-O-benzylvaline hydrochloride 在 二苯基膦叠氮化物 、 三乙胺 作用下， 生成 (S)-2-((S)-3-Benzyloxycarbonyl-2-{3-[3-(4-cyano-phenoxy)-propyl]-ureido}-propionylamino)-3-methyl-butyric acid benzyl ester
  参考文献：
  名称：

  Design, synthesis, and evaluation of orally active fibrinogen inhibitors

  摘要：

  Low molecular weight and orally active fibrinogen inhibitors are described. The compounds studied in this work were rationally designed based on a metabolic study of a peptidic fibrinogen inhibitor, 4-(4-amidinophenoxy)butanoylaspartylvaline (1, FK633), which led to the synthesis of a potent and orally active antiplatelet agent, 4-(4-amidinophenoxy)butanoylaspartylvalylthiomorpholine 1,1-dioxide (3 f, FR158999). (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00055-3